Cognito raises $35M, launches Alzheimer’s biomarker study

Feb 1, 2024 · Cognito Therapeutics Inc. closed a $35 million extension to the series B fundraising round it started in 2023, bringing the total for the round to $108 million and the total funding to …

CouponFollow Extension

$35
OFF

Cognito Raises $35M, Launches Alzheimer’s Biomarker Study

6 days from now

bioworld.com

$35
OFF

FirstWord HealthTech On LinkedIn: Cognito Nets $35 Million To …

6 days from now

Cognito Therapeutics, Inc. has raised $35 million to advance its digital ... Cognito nets $35 million to advance Alzheimer's DTx trial ... Decentralised trials firm Science 37 to go private in ...

linkedin.com

$73
OFF

Cognito Collects $73M For Light-and-sound Alzheimer's Therapy

6 days from now

Mar 22, 2023 · Cognito beams up $73M for study of light-and-sound neuromod therapy to treat Alzheimer's. Riding high on early clinical trial results showing that its neuromodulation headset …

fiercebiotech.com

$70
OFF

Cognito Taps Former BrainStorm President As Medical Chief - Fierce …

6 days from now

Apr 17, 2023 · With a pivotal trial of its neuromodulation treatment for Alzheimer’s disease underway—and backed by a fresh influx of more than $70 million in VC funding—Cognito …

fiercebiotech.com

$73
OFF

Cognito's Experimental Headset To Treat Alzheimer's Disease

6 days from now

Mar 22, 2023 · Cognito Therapeutics raised $73 million to test this theory in hundreds of people. For decades, biotech companies have struggled to develop treatments for Alzheimer's …

businessinsider.com

FAQs about Cognito raises $35M, launches Alzheimer’s biomarker study Coupon?

Is Cognito a breakthrough drug for Alzheimer's disease?

Brent Vaughn, chief executive officer of Cognito Therapeutics, expressed excitement about the data announcement in a statement and added, “With our recent FDA breakthrough device designation, we look forward to expediting the clinical development of what has the promise to be the first disease-modifying digital therapeutic in Alzheimer’s disease.” ...

Can a new drug help treat Alzheimer's disease?

J ust as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the neurodegenerative disease. ...

What is Cognito Therapeutics?

About Cognito Therapeutics Cognito Therapeutics is a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease. ...

What is Cognito therapeutic's next-generation neurostimulation device?

Cognito Therapeutic’s next-generation neurostimulation device for treating Alzheimer’s symptoms has won breakthrough designation from the FDA. ...

Does Cognito help Alzheimer's patients?

Compared with the placebo group, those who got the Cognito stimulation showed a 77 percent slowing in functional decline as measured by a scale that assesses how well Alzheimer’s patients are able to carry out daily activities, such as eating, dressing, and getting around. ...

Could a new headset help treat Alzheimer's?

The Cambridge, Massachusetts–based company is developing a headset to combat cognitive decline. In results from a Phase II trial published March 6 in the journal Frontiers in Neurology, the company showed that its novel treatment is safe and reported early hints that it may also have benefits for Alzheimer’s patients. ...